89bio Presents New Analysis of Data from Phase 2 ENTRIGUE

– Post hoc analysis data demonstrated pegozafermin treatment significantly reduced triglycerides and other atherogenic lipids in patients with SHTG regardless of their background lipid-modifying therapy status –

SAN FRANCISCO, March 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC). The presentation featured results of a post hoc analysis exploring the effect of pegozafermin treatment on lipids among study participants based on their background lipid-modifying therapy (LMT) status. These results were presented by Deepak L. Bhatt, M.D., M.P.H., Director of Mount Sinai Heart and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, and a copy of the poster is accessible under “Scientific Publications” in the pipeline section of 89bio’s website.

“We are encouraged by this additional data from the Phase 2 ENTRIGUE trial demonstrating significant reductions in triglycerides and a positive impact on atherogenic lipids with pegozafermin when added to background therapy, including high intensity statins, in patients with SHTG,” said Hank Mansbach, Chief Medical Officer of 89bio. “The overall positive ENTRIGUE data continues to support the advancement of pegozafermin into a pivotal Phase 3 program in SHTG. As the only FGF21 analog in development for the treatment of SHTG, we believe with its compelling and differentiated profile, pegozafermin could become an important new cardiometabolic medicine.”

The company previously announced that the randomized, double-blind ENTRIGUE trial met the primary endpoint of statistically significant reductions in median TGs from baseline in patients treated with 27mg of pegozafermin given weekly compared to placebo after 8 weeks (62% vs. 51%, for patients not on background therapy; p=0.013, and 68% vs. 59% for patients on background therapy; p=0.012). Significant reductions in TGs were observed consistently across all prespecified patient subgroups. The trial also met numerous secondary endpoints, including improvements in atherogenic lipoproteins, metabolic measures and liver fat. Approximately 50% of patients in ENTRIGUE were on concomitant lipid-modifying therapy, which is representative of the real-world setting. Pegozafermin was generally safe and well-tolerated.

Of the 85 ENTRIGUE study participants randomized and treated with pegozafermin or placebo, 55% were on background lipid-modifying therapy (45% on statin therapy of which 55% were on high intensity statins, 14% on prescription fish oil, and 7% on fibrates). Results of the post hoc analysis of lipid effects of pegozafermin among study participants based on their lipid-modifying background therapy status demonstrated that pegozafermin significantly reduced TG and other atherogenic lipids after eight weeks of therapy. Pegozafermin also led to reductions in TGs among patients on background high-intensity statins compared with placebo.

Median Percent Change in TG from Baseline at Week 8

N= (placebo, pegozafermin pooled)PlaceboPegozafermin27 mg QW
Background Therapy
Yes (n=11, 34)-18%-59%**-68%****
No (n=6, 30)5%-51%***-62%*****
High Intensity Statins
Yes (n=4,16)-6%-58%-72%

p value vs placebo for change from baseline based on Wilcoxon Rank-Sum Test
**p=0.001, ***p=0.004, ****p=0.012, *****p=0.013

As previously reported, pegozafermin-treated patients reached their initial treatment goal (i.e., a reduction in their TG level to less than 500 mg/dL) irrespective of background therapy. In the overall study population, 80% of those treated with pegozafermin reached their initial treatment goal compared with 29% of those on placebo (p<0.001). Among those on lipid-modifying background therapy, the comparable figures were 85% and 46%, respectively (p<0.05); among those not on background therapy, the comparable figures were 73% and 0%, respectively (p<0.01).

Treatment with pegozafermin also led to improvements in non-HDL cholesterol irrespective of background therapy; however, among study participants on background therapy those decreases were more robust. Improvements in apolipoprotein B (apo-B), a key marker of cardiovascular risk and a direct measure of the number of atherogenic particles, were observed irrespective of background therapy, and there were no significant changes in levels of LDL-cholesterol across the participants.

Median Percent Change in Non-HDL Cholesterol, Apo-B, and LDL-cholesterol from Baseline at Week 8

Dosing GroupNon-HDL
Placebo (Overall Population)-1%1%9%
Overall Pegozafermin Treated Population  -18%*-11%*10%
Placebo (Patients on Background Therapy)-7%-1%11%
Pegozafermin Treated Patients on Background Therapy  -29%-18%2%

*p<0.05 versus placebo based on MMRM analysis

“This new analysis builds on the growing body of evidence demonstrating that treatment with pegozafermin can significantly reduce triglycerides and improve markers of atherogenic risk across a wide variety of patients with SHTG,” said Dr. Bhatt. “These findings are encouraging given the critical need for new therapeutic options that not only reduce triglyceride levels but also improve broader cardiometabolic risks for patients with SHTG regardless of their lipid-modifying treatment status.”

Dr. Bhatt receives research funding from 89bio.

The randomized, double-blind, placebo-controlled ENTRIGUE trial enrolled 85 patients with SHTG either on stable background therapy or not on any background therapy who were treated weekly or every two weeks with pegozafermin. The trial enrolled an advanced population with a high risk of cardiovascular disease as evidenced by mean baseline values of TGs of 733 mg/dL and non-HDL-C of 211 mg/dL; 43.5% had HbA1c ≥6.5%, and, in the subgroup of patients undergoing MRI-PDFF, liver fat content was 20.1%.

About severe hypertriglyceridemia (SHTG)
SHTG, a severe form of elevated serum triglycerides, is a rare but harmful and underappreciated condition that affects up to 4 million people in the United States. SHTG is commonly associated with obesity, metabolic syndrome, insulin resistance, type 2 diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). SHTG increases the risk of atherosclerotic cardiovascular events and acute pancreatitis, which is the primary consideration driving the urgent need to treat these patients. The current standard of care for SHTG includes lifestyle changes and medications that include fish oils (icosapent ethyl and omega-3 ethyl esters), fibrates, niacin and statins. However, studies have shown that these therapies only have a modest effect on triglycerides, with as many as 50% of people with SHTG unable to achieve a treatment goal of a triglyceride level less than 500 mg/dL on treatment. These therapies do not provide broader metabolic benefits and may even worsen other risk factors for cardiovascular disease.

About pegozafermin
Pegozafermin is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) being developed for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). FGF21 is an endogenous hormone that modulates important drivers of lipid metabolism and NASH including triglyceride reduction, glycemic control, steatosis, inflammation and fibrosis. Pegozafermin was specifically engineered using a unique glycoPEGylated technology to extend the half-life while maintaining potency.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through clinical development for the treatment of non-alcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Forward-looking Statements
Certain statements in this press release may constitute 'forward-looking statements' within the meaning of the federal securities laws, including, but not limited to, the therapeutic potential and clinical benefits of pegozafermin, the safety and tolerability profile of pegozafermin and 89bio’s clinical development plans for pegozafermin. Words such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' “anticipate,” “goal,” “opportunity,” 'develop,' 'plan' or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While 89bio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in 89bio's filings with the SEC), many of which are beyond 89bio's control and subject to change. Actual results could be materially different. Risks and uncertainties include: expectations regarding the clinical benefit and safety of pegozafermin; expectations regarding the initiation of the first Phase 3 trial in SHTG; 89bio’s ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; 89bio’s substantial dependence on the success of it lead product candidate; competition from competing products; expectations regarding FDA approval and feedback; the effect of the COVID-19 pandemic on 89bio’s clinical trials and business operations, and the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of 89bio’s capital resources and its ability to raise additional capital; and other risks and uncertainties identified in 89bio's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and other subsequent disclosure documents filed with the SEC. 89bio claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. 89bio expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:
Ryan Martins
Chief Financial Officer
[email protected]

PJ Kelleher
LifeSci Advisors, LLC
[email protected] 

Media Contact:
Sheryl Seapy
Real Chemistry
[email protected]

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE


AIM ImmunoTech to Participate in Solve M.E. and The

OCALA, Fla., Feb. 17, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the...

Neuronetics Sponsors the 5th International Brain

Poster Session Highlights the Strong Dose-Response Relationship and the Importance of Treating Beyond 30 Treatments With NeuroStar Advanced Therapy...

Celldex Therapeutics Presents Positive Data from

- Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential...

Caribou Biosciences, Inc. (CRBU) Shareholder Alert: Robbins

SAN DIEGO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons or...

Summit Rehabilitation Opens New Outpatient Physical Therapy

Lynnwood, Wash., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Summit Rehabilitation, a network partner of Physical Rehabilitation Network (PRN), a leading US-based,...

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 26, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

Jowin, the Apple in Korea’s cancer treatment, expands their business globally

SEOUL, South Korea, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Jowin , which has shown great results in clinical trials of many stage 4 and terminal cancer patients in Korea over the past few years, sets this year as its first year of entering the global

New Clinical Studies Demonstrate that Sword Health Improves

The studies are the first to evaluate how underserved patient populations progress when given access to a digital care program- In Study #1 Black and...


Cách đặt phòng khách sạn với Agoda, chọn phòng giá rẻ

Sử dụng Agoda la cách giúp bạn có được căn phòng giá rẻ mà tốt nhất, hơn thế nữa đặt phòng khách sạn với Agoda bạn còn nhận được rất nhiều ưu đãi chính là từ ứng dụng cũng như các đối tác liên kết với Agoda.

Cách đặt ảnh 360 độ làm ảnh bìa trên Facebook

Khi cập nhật ứng dụng Facebook trên Android và iOS, nguồ dùng sẽ được sử dụng tính năng mới đặt ảnh 360 độ làm ảnh bìa trên Facebook.

Sửa lỗi Automatic Repair Loop trên Windows 10

Lỗi Automatic Repair Loop là một trong những lỗi gây nhiều khó chịu nhất cho người dùng máy tính Windows. Điều đáng nói là tính năng Automatic Repair được tích hợp sẵn trên Windows không bao giờ tự động sửa chữa các

Không thể tập trung làm việc vì mê Facebook? Hãy thử ứng dụng này

Chỉ cần cài đặt tiện ích Kill Newsfeed lên trình duyệt web Chrome, bạn sẽ nhận được một dòng hiển thị to đùng trên NewsFeed Facebook: Đừng để Facebook quyến rũ mình!

9 c&#225;ch khắc phục lỗi kh&#244;ng truy cập được v&#224;o Facebook

Người dùng Internet Việt Nam không thể truy cập vào được Facebook. Bạn đã thử nhiều cách, trong đó có thiết lập DNS mới (Google DNS, Open DNS, Norton DNS,…) cho máy tính nhưng không hiệu quả. Chưa biết rõ nguyên nhân


Đánh giá Honor Play: Lựa chọn không thể bỏ qua với những tín đồ của Gaming Mobile

Tuy là mẫu điện thoại được chú trọng vào hiệu suất chơi game, nhưng không vì thế mà những phần khác của Honor Play bị bỏ quên, trái lại còn được chăm chút khá tốt. Màn hình và thiết kế là một ví dụ, máy sở hữu màn hình

Trên tay máy nghe nhạc FiiO X3 Mark III: hoàn thiện tốt, hơi lag, chất âm tương xứng với giá 4,8tr

Với mức giá gần 5 triệu đồng, FiiO X3 Mark III mang đến cho chúng ta một chiếc máy nghe nhạc kích thước nhỏ gọn, vừa tay, nhẹ nhàng dễ cầm, chất lượng hoàn thiện máy tốt với thiết kế đơn giản, phần mềm điều khiển duyệt

Hongqi E-HS9 - Xứng danh "Rolls-Royce của Trung Quốc"

Thiết kế “chuẩn” Rolls-Royce, khoang nội thất tràn ngập công nghệ, hệ truyền động điện mạnh mẽ và thân thiện với môi trường, cảm giác lái ổn định,... Tất cả đều được gói gọn trong một chiếc xe được mệnh danh là